Astrazeneca (AZN) Research & Development (2016 - 2025)
Historic Research & Development for Astrazeneca (AZN) over the last 16 years, with Q4 2025 value amounting to -$3.9 billion.
- Astrazeneca's Research & Development rose 1742.57% to -$3.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$14.2 billion, marking a year-over-year decrease of 477.8%. This contributed to the annual value of -$14.2 billion for FY2025, which is 477.8% down from last year.
- According to the latest figures from Q4 2025, Astrazeneca's Research & Development is -$3.9 billion, which was up 1742.57% from -$3.7 billion recorded in Q3 2025.
- In the past 5 years, Astrazeneca's Research & Development registered a high of -$302.0 million during Q1 2021, and its lowest value of -$4.7 billion during Q4 2024.
- Its 5-year average for Research & Development is -$2.8 billion, with a median of -$2.7 billion in 2023.
- Per our database at Business Quant, Astrazeneca's Research & Development soared by 7824.21% in 2021 and then plummeted by 60629.14% in 2022.
- Quarter analysis of 5 years shows Astrazeneca's Research & Development stood at -$2.6 billion in 2021, then decreased by 1.59% to -$2.6 billion in 2022, then dropped by 17.07% to -$3.1 billion in 2023, then tumbled by 52.2% to -$4.7 billion in 2024, then grew by 17.43% to -$3.9 billion in 2025.
- Its Research & Development was -$3.9 billion in Q4 2025, compared to -$3.7 billion in Q3 2025 and -$3.5 billion in Q2 2025.